Evidence map›Paper›PMID 34034714›Full record

ArticleBMC complementary medicine and therapies2021

Homogeneous polyporus polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor microenvironment.

Wenyu Jia, Siwan Luo, Gena Lai, Shiqi Li, Shuai Huo, Meifang Li, Xing Zeng

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. HomogeneousPharmaceutical biology · 2024
    Article
  8. Molecules (Basel, Switzerland) · 2023
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenyu JiaThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Siwan LuoThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Gena LaiThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Shiqi LiThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Shuai HuoThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Meifang LiThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China.
Xing ZengThe Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, 510120, Guangdong Province, China. zengxing@gzucm.edu.cn.
Guangdong Provincial Hospital of Traditional Chinese Medicine · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolyporus polysaccharide (PPS), an active ingredient of traditional Chinese medicinal Polyporus umbellatus, has multiple biological functions, such as anti-cancer, immune-regulating and hepatoprotective activities. The purpose of this study was to investigate the mechanism of homogeneous polyporus polysaccharide (HPP) activated macrophages in the treatment of bladder cancer.

methods100 ng/mL Phorbol myristate acetate (PMA) was used to induce THP-1 human leukemic cells as a macrophage model. Then macrophages derived from THP-1 were treated with different concentrations of HPP (1, 10 and 100 μg/mL). Flow cytometry and RT-PCR were used to detected the expression of CD16, CD23, CD86, CD40 and interleukin (IL)-Iβ, iNOS mRNA. ELISA was used to test the change of IL-1β and TNF-α in macrophage after the treatment with HPP. The conditioned medium from HPP-polarized macrophages was used to detect the effect of activated macrophages on bladder cancer. MTT assay, 5-ethynyl-2'-deoxyuridine assay, flow cytometry, Transwell assay, and Western blot analysis were used to detect the effects of polarized macrophages on the viability, proliferation, apoptosis, and migration of bladder cancer cells. Western blot was also used to analysis the change of JAK2/NF-κB pathway protein.

resultsHPP promoted the expression of pro-inflammatory factors, such as IL-Iβ, TNF-α and iNOS, and surface molecules CD86, CD16, CD23, and CD40 in macrophages and then polarized macrophages to M1 type. Results demonstrated that activated macrophages inhibited the proliferation of bladder cancer cells, regulated their apoptosis, and inhibited migration and epithelial-mesenchymal transformation (EMT). JAK2/NF-κB pathways were downregulated in the anti-bladder cancer process of activated macrophages.

conclusionThe findings indicated that HPP inhibited the proliferation and progression of bladder cancer by the polarization of macrophages to M1 type, and JAK2/NF-κB pathway was downregulated in the process of anti-bladder cancer.

Indexed as

CytokinesFungal PolysaccharidesHumansJanus Kinase 2MacrophagesNF-kappa BPolyporusSignal TransductionTHP-1 CellsTumor MicroenvironmentUrinary Bladder NeoplasmsCytokinesFungal PolysaccharidesJAK2 protein, humanJanus Kinase 2NF-kappa BBladder cancerHomogeneous polyporus polysaccharideJAK2/NF-κB pathwayTHP-1-derived macrophageTumor microenvironment

Identifiers

PMID34034714
PMCPMC8152148
OpenAlexW3165249363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.